Ravi P Sahu
Ph.D.
Department of PHARMACOLOGY & TOXICOLOGY
Wright State University
United States of America
Biography
EDUCATION B.S.: University of Allahabad, Allahabad, India M.S.: Dr. R.M.L. Avadh University, Faizabad, India Ph.D.: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India POSTDOCTORAL TRAINING University of Pittsburgh Medical Center, Pittsburgh, PA Texas Tech University Health Sciences Center, Amarillo, TX Indiana University School of Medicine, Indianapolis, IN
Research Interest
RESEARCH INTERESTS: The long term research interests of his laboratory are: To investigate mechanisms of pro-oxidative stressors including ultraviolet B (UVB) and cigarette smoke generated oxidized lipids with platelet-activating factor (PAF) agonists activity in the modulation of cancer growth and metastasis, primarily melanoma and lung carcinoma. To determine mechanisms of tumor immune responses triggered by PAF-agonists in the effectiveness of melanoma and lung cancer therapies including immunotherapy. To evaluate effects of potentially applicable pharmacological and combination approaches including PAF-R antagonists to enhance the efficacy of melanoma therapies. They explore several cellular and molecular biology techniques including cell proliferation, survival and migration assays, gene deletion and overexpression, PCR, real time RT-PCR, ELISA, western blotting, and flow cytometry. In addition, we utilize various in vitro cell culture systems, in vivo mouse models of various strains including knockouts and transgenics as well as human samples in our research.
Publications
-
Sahu RP, Ocana JA, Harrison KA, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK, Perkins SM, Speicher PJ, Tyler DS, Konger RL, Travers JB. Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Research. 2014; 74(23):7069-78.
-
Thyagarajan A, Sahu RP*. Potential contributions of antioxidants to cancer therapy: Immunomodulation and Radiosensitization. Integrative Cancer Therapy. 2017. doi: 10.1177/1534735416681659.
-
Thyagarajan A, Saylae J, Sahu RP*. Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathways. Oncotarget. 2017, 8(30):49959-49972.